+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Interleukin Inhibitors for the Treatment of Refractory Gout Market - Global Forecast 2025-2030- Product Image
Interleukin Inhibitors for the Treatment of Refractory Gout Market - Global Forecast 2025-2030- Product Image
Sale

Interleukin Inhibitors for the Treatment of Refractory Gout Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 185 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6135101
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior decision-makers focused on evolving specialty therapeutics will find the Interleukin Inhibitor Market for Refractory Gout poised at the intersection of innovation and clinical differentiation. This report offers a concise, data-driven overview, highlighting how targeted immunomodulation, emerging commercial frameworks, and regionally nuanced strategies are converging to transform patient care and stakeholder returns.

Market Snapshot: Refractory Gout and Interleukin Inhibitors

The global interleukin inhibitor market addressing refractory gout is experiencing substantial momentum, driven by advances in immunology and biotechnology. Adoption of targeted biologic agents is accelerating as precision medicine takes precedence in managing persistent joint inflammation that remains unresponsive to conventional urate-lowering therapies. Stakeholders are responding to mounting payer scrutiny and increased demand for patient-centric solutions.

Scope & Segmentation: Complete Market Coverage

This market research provides a comprehensive framework for understanding product positioning, therapy delivery, and evolving stakeholder needs across the refractory gout landscape. Segmentation allows granular analysis by product, administration, end user, and region.

  • Product Types: Anakinra, Canakinumab, Rilonacept, offered in pre-filled syringes and vials to match diverse clinical workflows.
  • End Users: Covering homecare providers, hospitals (private and public), and specialty clinics such as orthopedic and rheumatology centers.
  • Route of Administration: Encompasses both intravenous and subcutaneous injection, supporting personalized therapeutic choices.
  • Distribution Channels: Includes hospital (centralized and satellite), retail, and online pharmacies for broad-based market access.
  • Dosage Forms: Features pre-filled pens, pre-filled syringes, and vials in both multi-dose and single-dose configurations.
  • Treatment Setting: Analyzes inpatient versus outpatient usage patterns to reflect changing clinical pathways.
  • Patient Categories: Examines adult, elderly, and pediatric populations with attention to age-related pharmacokinetics.
  • Regional Coverage: Segments Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (UK, Germany, France, and others), and Asia-Pacific (China, India, Japan, and additional markets).
  • Leading Companies: Profiles Novartis AG, Regeneron Pharmaceuticals, Inc., Sanofi S.A., and Swedish Orphan Biovitrum AB.

Key Takeaways: Strategic Insights for Senior Decision-Makers

  • The market is shaped by increasing demand for targeted immunomodulation, particularly interleukin-1 inhibitors, which intervene at the source of refractory inflammation.
  • Real-world evidence integration streamlines adoption in diverse healthcare settings, supporting rapid standard-of-care transitions and improved patient outcomes.
  • Segment growth is catalyzed by flexible administration models, including decentralized delivery through homecare and outpatient clinics, meeting the needs of varied patient populations.
  • Local regulatory landscapes, from robust payer networks in the Americas to government-driven reforms in Asia-Pacific, strongly influence therapy uptake and commercial strategies.
  • Strategic collaborations among leading biopharmaceutical firms and emerging technology partners are accelerating expanded indications and pipeline diversification.
  • Patient support initiatives—such as digital adherence solutions and virtual education—are increasingly pivotal for real-world effectiveness and lasting therapy engagement.

Tariff Impact: 2025 United States Supply Chain Shifts

The proposed 2025 US tariffs will apply incremental levies to imported biologic ingredients and finished interleukin inhibitors, affecting both input costs and manufacturing strategies. Manufacturers are reviewing supply chains, considering near-shoring, and building strategic sourcing alliances to reduce disruption. Distribution and payer negotiations may need realignment as higher input costs translate into new pricing dynamics, prompting expanded co-pay assistance and value-based contracting to preserve therapy access.

Research Methodology & Data Sources

This report’s findings result from in-depth interviews with key opinion leaders in rheumatology, pharmacy, and health economics, paired with a comprehensive analysis of peer-reviewed studies, regulatory submissions, and proprietary treatment data. Quantitative modeling and external validation from industry experts further reinforce data integrity.

The Value: Why This Report Matters

  • Senior leadership can rapidly assess which market segments and geographies offer the best margin resilience and growth potential.
  • Actionable information supports strategic planning, procurement adjustments, and pricing negotiations in the face of evolving reimbursement and regulatory environments.

The report equips decision-makers to identify emerging trends and define leadership positions within refractory gout therapeutics.

Conclusion

Interleukin inhibitor adoption in refractory gout is advancing on multiple fronts, shaped by clinical innovation, adaptive commercialization, and changing global supply chain realities. Stakeholders who act on these insights will be positioned to capture value as the market continues to evolve.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emerging clinical evidence supporting IL-1ß inhibitors efficacy in chronic refractory gout flare management
5.2. Pharmacoeconomic analysis of long term IL-1 inhibitor therapy cost effectiveness in refractory gout
5.3. Real world safety profile comparison of anakinra versus canakinumab in treatment resistant gout patients
5.4. Pipeline developments in next generation interleukin inhibitors targeting IL-6 and IL-17 pathways for refractory gout
5.5. Impact of personalized dosing strategies based on genetic biomarkers on interleukin inhibitor treatment outcomes for gout
5.6. Emergence of subcutaneous versus intravenous administration preferences influencing IL inhibitor adoption in refractory gout
5.7. Regulatory updates on biosimilar interleukin antagonist approvals and their effect on refractory gout therapy costs
5.8. Integration of digital health monitoring tools to track interleukin inhibitor response in chronic gout management programs
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Interleukin Inhibitors for the Treatment of Refractory Gout Market, by Product
8.1. Introduction
8.2. Anakinra
8.2.1. Pre-Filled Syringe
8.2.2. Vial
8.3. Canakinumab
8.3.1. Pre-Filled Syringe
8.3.2. Vial
8.4. Rilonacept
8.4.1. Pre-Filled Syringe
8.4.2. Vial
9. Interleukin Inhibitors for the Treatment of Refractory Gout Market, by End User
9.1. Introduction
9.2. Homecare Providers
9.3. Hospitals
9.3.1. Private Hospitals
9.3.2. Public Hospitals
9.4. Specialty Clinics
9.4.1. Orthopedic Clinics
9.4.2. Rheumatology Clinics
10. Interleukin Inhibitors for the Treatment of Refractory Gout Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous Injection
10.3. Subcutaneous Injection
11. Interleukin Inhibitors for the Treatment of Refractory Gout Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.2.1. Centralized Pharmacies
11.2.2. Satellite Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Interleukin Inhibitors for the Treatment of Refractory Gout Market, by Dosage Form
12.1. Introduction
12.2. Pre-Filled Pen
12.2.1. Multi-Dose
12.2.2. Single-Dose
12.3. Pre-Filled Syringe
12.3.1. Multi-Dose
12.3.2. Single-Dose
12.4. Vial
12.4.1. Multi-Dose
12.4.2. Single-Dose
13. Interleukin Inhibitors for the Treatment of Refractory Gout Market, by Treatment Setting
13.1. Introduction
13.2. Inpatient
13.3. Outpatient
14. Interleukin Inhibitors for the Treatment of Refractory Gout Market, by Patient Category
14.1. Introduction
14.2. Adult
14.3. Elderly
14.4. Pediatric
15. Americas Interleukin Inhibitors for the Treatment of Refractory Gout Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Interleukin Inhibitors for the Treatment of Refractory Gout Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Novartis AG
18.3.2. Regeneron Pharmaceuticals, Inc.
18.3.3. Sanofi S.A.
18.3.4. Swedish Orphan Biovitrum AB
19. ResearchAI20. ResearchStatistics21. ResearchContacts22. ResearchArticles23. Appendix
List of Figures
FIGURE 1. INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
FIGURE 6. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 8. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2030 (%)
FIGURE 16. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT CATEGORY, 2024 VS 2030 (%)
FIGURE 18. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT CATEGORY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET: RESEARCHAI
FIGURE 30. INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET: RESEARCHSTATISTICS
FIGURE 31. INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET: RESEARCHCONTACTS
FIGURE 32. INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ANAKINRA, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ANAKINRA, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ANAKINRA, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ANAKINRA, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CANAKINUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CANAKINUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CANAKINUMAB, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CANAKINUMAB, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RILONACEPT, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RILONACEPT, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RILONACEPT, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RILONACEPT, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOMECARE PROVIDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOMECARE PROVIDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORTHOPEDIC CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORTHOPEDIC CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RHEUMATOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RHEUMATOLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CENTRALIZED PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CENTRALIZED PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SATELLITE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SATELLITE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED PEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED PEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MULTI-DOSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MULTI-DOSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SINGLE-DOSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SINGLE-DOSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED PEN, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED PEN, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MULTI-DOSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MULTI-DOSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SINGLE-DOSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SINGLE-DOSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MULTI-DOSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MULTI-DOSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SINGLE-DOSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SINGLE-DOSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT CATEGORY, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT CATEGORY, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ELDERLY, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ELDERLY, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ANAKINRA, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ANAKINRA, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CANAKINUMAB, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CANAKINUMAB, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RILONACEPT, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RILONACEPT, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED PEN, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED PEN, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT CATEGORY, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT CATEGORY, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ANAKINRA, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ANAKINRA, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CANAKINUMAB, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CANAKINUMAB, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RILONACEPT, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RILONACEPT, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED PEN, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED PEN, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT CATEGORY, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT CATEGORY, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 183. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 184. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 185. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ANAKINRA, 2018-2024 (USD MILLION)
TABLE 186. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ANAKINRA, 2025-2030 (USD MILLION)
TABLE 187. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CANAKINUMAB, 2018-2024 (USD MILLION)
TABLE 188. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CANAKINUMAB, 2025-2030 (USD MILLION)
TABLE 189. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RILONACEPT, 2018-2024 (USD MILLION)
TABLE 190. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RILONACEPT, 2025-2030 (USD MILLION)
TABLE 191. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 194. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 195. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 196. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 197. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 198. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 199. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 200. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 201. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 202. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 203. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 204. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 205. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED PEN, 2018-2024 (USD MILLION)
TABLE 206. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED PEN, 2025-2030 (USD MILLION)
TABLE 207. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 208. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 209. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
TABLE 210. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY VIAL, 2025-2030 (USD MILLION)
TABLE 211. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 212. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 213. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT CATEGORY, 2018-2024 (USD MILLION)
TABLE 214. CANADA INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT CATEGORY, 2025-2030 (USD MILLION)
TABLE 215. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 216. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 217. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ANAKINRA, 2018-2024 (USD MILLION)
TABLE 218. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ANAKINRA, 2025-2030 (USD MILLION)
TABLE 219. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CANAKINUMAB, 2018-2024 (USD MILLION)
TABLE 220. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CANAKINUMAB, 2025-2030 (USD MILLION)
TABLE 221. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RILONACEPT, 2018-2024 (USD MILLION)
TABLE 222. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RILONACEPT, 2025-2030 (USD MILLION)
TABLE 223. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 224. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 225. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 226. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 227. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 228. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 229. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 230. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 231. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 234. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 235. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 236. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 237. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED PEN, 2018-2024 (USD MILLION)
TABLE 238. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED PEN, 2025-2030 (USD MILLION)
TABLE 239. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 240. MEXICO INTERLEUKIN INHIBITORS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRE-FILLED SYRINGE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Interleukin Inhibitors for the Treatment of Refractory Gout Market report include:
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Swedish Orphan Biovitrum AB

Related Topics

Related Reports

Drugs for the Treatment of Refractory Gout Market - Global Forecast 2025-2030 - Product Image

Drugs for the Treatment of Refractory Gout Market - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Interleukin 1 Beta Inhibitors - Pipeline Insight, 2025 - Product Image

Interleukin 1 Beta Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Chronic Refractory Gout - Pipeline Insight, 2025 - Product Image

Chronic Refractory Gout - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Interleukin Inhibitors for Psoriasis Market - Global Forecast 2025-2030 - Product Image

Interleukin Inhibitors for Psoriasis Market - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Interleukin Inhibitors Market Report 2025 - Product Image

Interleukin Inhibitors Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.